

7. Literatur

- Agrawal R, Lichtenstein I, Siebe H, Hierholzer K. In vitro 6 beta-hydroxylation of progesterone in human renal tissue. *Wien Klin Wochenschr* 1997; 109:493-496.
- Anakk S, Ku CY, Vore M, Strobel HW. Insights into Gender Bias: Rat Cytochrome P450 3A9. *J Pharmacol Exp Ther* 2003; 305:703-709.
- Anglicheau D, Thervet E, Etienne I, Hurault De Ligny B, Le Meur Y, Touchard G, Buchler M, Laurent-Puig P, Tregouet D, Beaune P, Daly A, Legendre C, Marquet P. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. *Clin Pharmacol Ther* 2004; 75:422-433.
- Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, Gelboin HV. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. *J Biol Chem* 1989; 264:10388-10395.
- Burk O, Wojnowski L. Cytochrome P450 3A and their regulation. *Naunyn Schmiedeberg's Arch Pharmacol* 2004; 369:105-124.
- Burk O, Tegude H, Koch I, Hustert E, Wolbold R, Glaeser H, Klein K, Fromm MF, Nuessler AK, Neuhaus P, Zanger UM, Eichelbaum M, Wojnowski L. Molecular Mechanisms of Polymorphic CYP3A7 Expression in Adult Human Liver and Intestine. *J Biol Chem* 2002; 277:24280-24288.
- Busauschina A, Schnuelle P, van der Woude FJ. Cyclosporine nephrotoxicity. *Transplant Proc* 2004; 36:229S-233S.
- Cairns HS, Rogerson M, Fairbanks LD, Westwick J, Neild GH. Endothelin and cyclosporin nephrotoxicity. *Lancet* 1988; 2:1496-1497.
- Cattaneo D, Perico N, Gaspari F, Remuzzi G. Nephrotoxic aspects of cyclosporine. *Transplant Proc* 2004; 36:234S-239S.
- Chou FC, Tzeng SJ, Huang Jd. Genetic Polymorphism of Cytochrome P450 3A5 in Chinese. *Drug Metab Dispos* 2001; 29:1205-1209.
- Christians U, Sewing KF. Alternative cyclosporine metabolic pathways and toxicity. *Clin Biochem* 1995; 28:547-559.
- Cifkova R, Hallen H. Cyclosporin-induced hypertension. *J Hypertens* 2001; 19:2283-2285.
- Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. *Clin Pharmacokinet* 2005; 44:33-60.
- Cummings BS, Zangar RC, Novak RF, Lash LH. Cellular Distribution of Cytochromes P-450 in the Rat Kidney. *Drug Metab Dispos* 1999; 27:542-548.
- Dai Y, Iwanaga K, Lin YS, Hebert MF, Davis CL, Huang W, Kharasch ED, Thummel KE. In vitro metabolism of cyclosporine A by human kidney CYP3A5. *Biochem Pharmacol* 2004; 68:1889-1902.
- Daly AK. Significance of the minor cytochrome P450 3A isoforms. *Clin Pharmacokinet* 2006; 45:13-31.

- de Jong PE, Hillege HL, Pinto-Sietsma SJ, de Zeeuw D. Screening for microalbuminuria in the general population: a tool to detect subjects at risk for progressive renal failure in an early phase? *Nephrol Dial Transplant* 2003; 18:10-13.
- de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. *Clin Pharmacokinet* 1999; 37:485-505.
- Debri K, Boobis AR, Davies DS, Edwards RJ. Distribution and induction of CYP3A1 and CYP3A2 in rat liver and extrahepatic tissues. *Biochem Pharmacol* 1995; 50:2047-2056.
- Duncan RL, Grogan WM, Kramer LB, Watlington CO. Corticosterone's metabolite is an agonist for Na⁺ transport stimulation in A6 cells. *Am J Physiol Renal Physiol* 1988; 255:F736-F748.
- Eichelbaum M, Burk O. CYP3A genetics in drug metabolism. *Nat Med* 2001; 7:285-287.
- Farman N, Rafestin-Oblin ME. Multiple aspects of mineralocorticoid selectivity. *Am J Physiol Renal Physiol* 2001; 280:F181-F192.
- Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. *Drugs* 1993; 45:953-1040.
- Ferrari P, Lovati E, Frey FJ. The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension. *J Hypertens* 2000; 18:241-248.
- Fromm MF, Schmidt BM, Pahl A, Jacobi J, Schmieider RE. CYP3A5 genotype is associated with elevated blood pressure. *Pharmacogenet Genomics* 2005; 15:737-741.
- Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. *Science* 1988; 242:583-585.
- Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, Haberl M, Deglmann CJ, Burk O, Buntfuss D, Escher S, Bishop C, Koebe HG, Brinkmann U, Klenk HP, Kleine K, Meyer UA, Wojnowski L. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. *Pharmacogenetics* 2001; 11:111-121.
- Ghosh S, Grogan WM, Basu A, Watlington C. Renal corticosterone 6 beta-hydroxylase in the spontaneously hypertensive rat. *Biochim Biophys Acta* 1993; 1182:152-156.
- Ghosh SS, Basu AK, Ghosh S, Hagley R, Kramer L, Schuetz J, Grogan WM, Guzelian P, Watlington CO. Renal and hepatic family 3A cytochromes P450 (CYP3A) in spontaneously hypertensive rats. *Biochem Pharmacol* 1995; 50:49-54.
- Givens RC, Lin YS, Dowling ALS, Thummel KE, Lamba JK, Schuetz EG, Stewart PW, Watkins PB. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. *J Appl Physiol* 2003; 95:1297-1300.
- Gonzalez FJ, Nebert DW, Hardwick JP, Kasper CB. Complete cDNA and protein sequence of a pregnenolone 16 alpha- carbonitrile-induced cytochrome P-450. A representative of a new gene family. *J Biol Chem* 1985; 260:7435-7441.
- Gonzalez FJ, Song BJ, Hardwick JP. Pregnenolone 16 alpha-carbonitrile-inducible P-450 gene family: gene conversion and differential regulation. *Mol Cell Biol* 1986; 6:2969-2976.

- Goto M, Masuda S, Kiuchi T, Ogura Y, Oike F, Okuda M, Tanaka K, Inui K. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. *Pharmacogenetics* 2004; 14:471-478.
- Grogan WM, Phillips VM, Schuetz EG, Guzelian PS, Watlington CO. Corticosterone 6 beta-hydroxylase in A6 epithelia: a steroid-inducible cytochrome P-450. *Am J Physiol Cell Physiol* 1990; 258:C480-C488.
- Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. *Annu Rev Pharmacol Toxicol* 1999; 39:1-17.
- Guengerich FP, MacDonald TL. Mechanisms of cytochrome P-450 catalysis. *FASEB J* 1990; 4:2453-2459.
- Haas M, Mayer G. Cyclosporin A-associated hypertension--pathomechanisms and clinical consequences. *Nephrol Dial Transplant* 1997; 12:395-398.
- Haehner BD, Gorski JC, Vandenbranden M, Wrighton SA, Janardan SK, Watkins PB, Hall SD. Bimodal distribution of renal cytochrome P450 3A activity in humans. *Mol Pharmacol* 1996; 50:52-59.
- Hasler JA. Pharmacogenetics of cytochromes P450. *Mol Aspects Med* 1999; 20:12-24, 25.
- Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet JP, Wallemacq P. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. *Pharmacogenetics* 2004; 14:147-154.
- Hesselink DA, Smak Gregoor PJ, Weimar W. The use of cyclosporine in renal transplantation. *Transplant Proc* 2004a; 36:99S-106S.
- Hesselink DA, van Gelder T, van Schaik RH, Balk AH, van der Heiden IP, van Dam T, van der Werf M, Weimar W, Mathot RA. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. *Clin Pharmacol Ther* 2004b; 76:545-556.
- Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, van Gelder T. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. *Clin Pharmacol Ther* 2003; 74:245-254.
- Ho H, Pinto A, Hall SD, Flockhart DA, Li L, Skaar TC, Cadman P, O'Connor DT, Wagner U, Fineberg NS, Weinberger MH. Association Between the CYP3A5 Genotype and Blood Pressure. *Hypertension* 2005; 45:294-298.
- Huang W, Lin YS, McConn DJ, II, Calamia JC, Totah RA, Isoherranen N, Glodowski M, Thummel KE. Evidence Of Significant Contribution From CYP3A5 To Hepatic Drug Metabolism. *Drug Metab Dispos* 2004; 32:1434-1445.
- Huss JM, Wang SI, Astrom A, McQuiddy P, Kasper CB. Dexamethasone responsiveness of a major glucocorticoid-inducible CYP3A gene is mediated by elements unrelated to a glucocorticoid receptor binding motif. *Proceedings of the National Academy of Sciences* 1996; 93:4666-4670.

- Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockmoller J, Halpert JR, Zanger UM, Wojnowski L. The genetic determinants of the CYP3A5 polymorphism. *Pharmacogenetics* 2001; 11:773-779.
- Imaoka S, Funae Y. Hepatic and renal cytochrome P-450s in spontaneously hypertensive rats. *Biochim Biophys Acta* 1991; 1074:209-213.
- Ingelman-Sundberg M, Oscarson M, Daly AK, Garte S, Nebert DW. Human Cytochrome P-450 (CYP) Genes: A Web Page for the Nomenclature of Alleles. *Cancer Epidemiol Biomarkers Prev* 2001; 10:1307-1308.
- Jorga A, Holt DW, Johnston A. Therapeutic drug monitoring of cyclosporine. *Transplant Proc* 2004; 36:396S-403S.
- Jounaidi Y, Hyrailles V, Gervot L, Maurel P. Detection of CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein? *Biochem Biophys Res Commun* 1996; 221:466-470.
- Kahan BD, Welsh M, Schoenberg L, Rutzky LP, Katz SM, Urbauer DL, Van Buren CT. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. *Transplantation* 1996; 62:599-606.
- Kapturczak MH, Meier-Kriesche HU, Kaplan B. Pharmacology of calcineurin antagonists. *Transplant Proc* 2004; 36:25S-32S.
- Kelly P, Kahan BD. Review: metabolism of immunosuppressant drugs. *Curr Drug Metab* 2002; 3:275-287.
- Kivisto KT, Niemi M, Schaeffeler E, Pitkala K, Tilvis R, Fromm MF, Schwab M, Lang F, Eichelbaum M, Strandberg T. CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study. *Am J Pharmacogenomics* 2005; 5:191-195.
- Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, Nuessler A, Neuhaus P, Eichelbaum M, Zanger U, Wojnowski L. Interindividual Variability and Tissue-Specificity in the Expression of Cytochrome P450 3A mRNA. *Drug Metab Dispos* 2002; 30:1108-1114.
- Kreutz R, Zurcher H, Kain S, Martus P, Offermann G, Beige J. The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. *Pharmacogenetics* 2004; 14:665-671.
- Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. *Clin Pharmacol Ther* 1988; 43:630-635.
- Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. *Nat Genet* 2001; 27:383-391.
- Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. *Adv Drug Deliv Rev* 2002; 54:1271-1294.

- LeCluyse EL. Pregnane X receptor: molecular basis for species differences in CYP3A induction by xenobiotics. *Chem Biol Interact* 2001; 134:283-289.
- Lee SJ, Goldstein JA. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. *Pharmacogenomics* 2005; 6:357-371.
- Lee SJ, Usmani KA, Chanas B, Ghanayem B, Xi T, Hodgson E, Mohrenweiser HW, Goldstein JA. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. *Pharmacogenetics* 2003; 13:461-472.
- Lensmeyer GL, Wiebe DA, Carlson IH, deVos DJ. Three commercial polyclonal immunoassays for cyclosporine in whole blood compared: 2. Cross-reactivity of the antisera with cyclosporine metabolites. *Clin Chem* 1990; 36:119-123.
- Li AP, Kaminski DL, Rasmussen A. Substrates of human hepatic cytochrome P450 3A4. *Toxicology* 1995; 104:1-8.
- Lin YS, Dowling ALS, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, Thummel KE. Co-Regulation of CYP3A4 and CYP3A5 and Contribution to Hepatic and Intestinal Midazolam Metabolism. *Mol Pharmacol* 2002; 62:162-172.
- Lindholm A. Factors influencing the pharmacokinetics of cyclosporine in man. *Ther Drug Monit* 1991; 13:465-477.
- Litchfield WR, Hunt SC, Jeunemaitre X, Fisher NDL, Hopkins PN, Williams RR, Corvol P, Williams GH. Increased Urinary Free Cortisol : A Potential Intermediate Phenotype of Essential Hypertension. *Hypertension* 1998; 31:569-574.
- Mahnke A, Roos PH, Hanstein WG, Chabot GG. In vivo induction of cytochrome P450 CYP3A expression in rat leukocytes using various inducers. *Biochem Pharmacol* 1996; 51:1579-1582.
- Mahnke A, Strotkamp D, Roos PH, Hanstein WG, Chabot GG, Nef P. Expression and inducibility of cytochrome P450 3A9 (CYP3A9) and other members of the CYP3A subfamily in rat liver. *Arch Biochem Biophys* 1997; 337:62-68.
- Matsubara T, Kim HJ, Miyata M, Shimada M, Nagata K, Yamazoe Y. Isolation and Characterization of a New Major Intestinal CYP3A Form, CYP3A62, in the Rat. *J Pharmacol Exp Ther* 2004; 309:1282-1290.
- Merkus M, Jager K, Dekker F, de Haan R, Boeschoten E, Krediet R. Physical symptoms and quality of life in patients on chronic dialysis: results of The Netherlands cooperative study on adequacy of dialysis (NECOSAD). *Nephrol Dial Transplant* 1999; 14:1163-1170.
- Molowa DT, Schuetz EG, Wrighton SA, Watkins PB, Kremers P, Mendez-Picon G, Parker GA, Guzelian PS. Complete cDNA Sequence of a Cytochrome P-450 Inducible by Glucocorticoids in Human Liver. *PNAS* 1986; 83:5311-5315.
- Morozumi K, Takeda A, Uchida K, Mihatsch MJ. Cyclosporine nephrotoxicity: how does it affect renal allograft function and transplant morphology? *Transplant Proc* 2004; 36:251S-256S.

- Morris DJ, Latif SA, Rokaw MD, Watlington CO, Johnson JP. A second enzyme protecting mineralocorticoid receptors from glucocorticoid occupancy. *Am J Physiol Cell Physiol* 1998; 274:C1245-C1252.
- Murray GI, McFadyen MC, Mitchell RT, Cheung YL, Kerr AC, Melvin WT. Cytochrome P450 CYP3A in human renal cell cancer. *Br J Cancer* 1999; 79:1836-1842.
- Nagata K, Murayama N, Miyata M, Shimada M, Urahashi A, Yamazoe Y, Kato R. Isolation and characterization of a new rat P450 (CYP3A18) cDNA encoding P450(6)beta-2 catalyzing testosterone 6 beta- and 16 alpha-hydroxylations. *Pharmacogenetics* 1996; 6:103-111.
- Nagata K, Ogino M, Shimada M, Miyata M, Gonzalez FJ, Yamazoe Y. Structure and expression of the rat CYP3A1 gene: isolation of the gene (P450/6betaB) and characterization of the recombinant protein. *Arch Biochem Biophys* 1999; 362:242-253.
- Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. *Pharmacogenetics* 1996; 6:1-42.
- Niwa T, Yabusaki Y, Honma K, Matsuo N, Tatsuta K, Ishibashi F, Katagiri M. Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. *Xenobiotica* 1998; 28:539-547.
- Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. *Jpn Circ J* 1963; 27:282-293.
- Omura T, Sato R. The Carbon Monoxide-binding Pigment of Liver Microsomes. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. *J Biol Chem* 1964; 239:2370-2378.
- Ozdemir V, Kalowa W, Tang BK, Paterson AD, Walker SE, Endrenyi L, Kashuba AD. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. *Pharmacogenetics* 2000; 10:373-388.
- Paris PL, Kupelian PA, Hall JM, Williams TL, Levin H, Klein EA, Casey G, Witte JS. Association between a CYP3A4 Genetic Variant and Clinical Presentation in African-American Prostate Cancer Patients. *Cancer Epidemiol Biomarkers Prev* 1999; 8:901-905.
- Paul LC, de Fijter JH. Cyclosporine-induced renal dysfunction. *Transplant Proc* 2004; 36:224S-228S.
- Rapp JP. Genetic Analysis of Inherited Hypertension in the Rat. *Physiol Rev* 2000; 80:135-172.
- Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. *J Natl Cancer Inst* 1998; 90:1225-1229.
- Ribeiro V, Lechner MC. Cloning and characterization of a novel CYP3A1 allelic variant: analysis of CYP3A1 and CYP3A2 sex-hormone-dependent expression reveals that the CYP3A2 gene is regulated by testosterone. *Arch Biochem Biophys* 1992; 293:147-152.

- Robertson GR, Farrell GC, Liddle C. Sexually dimorphic expression of rat CYP3A9 and CYP3A18 genes is regulated by growth hormone. *Biochem Biophys Res Commun* 1998; 242:57-60.
- Schuetz EG, Schuetz JD, Grogan WM, Naray-Fejes-Toth A, Fejes-Toth G, Raucy J, Guzelian P, Gionela K, Watlington CO. Expression of cytochrome P450 3A in amphibian, rat, and human kidney. *Arch Biochem Biophys* 1992; 294:206-214.
- Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. *J Pharmacol Exp Ther* 1994; 270:414-423.
- Stoll M, Kwitek-Black AE, Cowley AW, Jr., Harris EL, Harrap SB, Krieger JE, Printz MP, Provoost AP, Sassard J, Jacob HJ. New Target Regions for Human Hypertension via Comparative Genomics. *Genome Res* 2000; 10:473-482.
- Strotkamp D, Roos PH, Hanstein WG. A novel CYP3 gene from female rats. *Biochim Biophys Acta* 1995; 1260:341-344.
- Takara K, Ohnishi N, Horibe S, Yokoyama T. Expression profiles of Drug-Metabolizing Enzyme CYP3A and Drug Efflux Transporter Multidrug Resistance 1 Subfamily mRNAs in rat small Intestine *Drug Metab Dispos* 2003; 31:1235-1239.
- Tayeb MT, Clark C, Sharp L, Haites NE, Rooney PH, Murray GI, Payne SN, McLeod HL. CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. *Oncol Rep* 2002; 9:653-655.
- Termorshuizen F, Dekker FW, van Manen JG, Korevaar JC, Boeschoten EW, Krediet RT. Relative Contribution of Residual Renal Function and Different Measures of Adequacy to Survival in Hemodialysis Patients: An analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. *J Am Soc Nephrol* 2004; 15:1061-1070.
- Thummel KE. Does the CYP3A5*3 polymorphism affect in vivo drug elimination? *Pharmacogenetics* 2003; 13:585-587.
- Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. *Annu Rev Pharmacol Toxicol* 1998; 38:389-430.
- Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K, Suzuki T, Habuchi T, Kato T. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. *Transplantation* 2004; 78:1182-1187.
- van Uum SH, Lenders JW, Hermus AR. Cortisol, 11beta-hydroxysteroid dehydrogenases, and hypertension. *Semin Vasc Med* 2004; 4:121-128.
- Wang H, Kawashima H, Strobel HW. cDNA cloning of a novel CYP3A from rat brain. *Biochem Biophys Res Commun* 1996; 221:157-162.
- Warrington JS, Greenblatt DJ, von Moltke LL. Age-Related Differences in CYP3A Expression and Activity in the Rat Liver, Intestine, and Kidney. *J Pharmacol Exp Ther* 2004; 309:720-729.
- Watkins PB. Drug metabolism by cytochromes P450 in the liver and small bowel. *Gastroenterol Clin North Am* 1992; 21:511-526.

- Watlington CO, Kramer LB, Schuetz EG, Zilai J, Grogan WM, Guzelian P, Gizek F, Schoolwerth AC. Corticosterone 6 beta-hydroxylation correlates with blood pressure in spontaneously hypertensive rats. *Am J Physiol Renal Physiol* 1992; 262:F927-F931.
- Watt GC, Harrap SB, Foy CJ, Holton DW, Edwards HV, Davidson HR, Connor JM, Lever AF, Fraser R. Abnormalities of glucocorticoid metabolism and the renin-angiotensin system: a four-corners approach to the identification of genetic determinants of blood pressure. *J Hypertens* 1992; 10:473-482.
- Waxman DJ, Attisano C, Guengerich FP, Lapenson DP. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. *Arch Biochem Biophys* 1988; 263:424-436.
- Werck-Reichhart D, Feyereisen R. Cytochromes P450: a success story. *Genome Biol* 2000; 1:REVIEWS3003-
- Westlind A, Malmebo S, Johansson I, Otter C, Andersson TB, Ingelman-Sundberg M, Oscarson M. Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. *Biochem Biophys Res Commun* 2001; 281:1349-1355.
- Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, Ingelman-Sundberg M. Comparative Analysis of CYP3A Expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. *Drug Metab Dispos* 2003; 31:755-761.
- Williams JA, Cook J, Hurst SI. A significant drug-metabolizing role for CYP3A5? *Drug Metab Dispos* 2003; 31:1526-1530.
- Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA. Comparative Metabolic Capabilities of CYP3A4, CYP3A5, and CYP3A7. *Drug Metab Dispos* 2002; 30:883-891.
- Wojnowski L. Genetics of the variable expression of CYP3A in humans. *Ther Drug Monit* 2004; 26:192-199.
- Wojnowski L, Hustert E, Klein K, Goldammer M, Haberl M, Kirchheiner J, Koch I, Klattig J, Zanger U, Brockmoller J. Re: Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in CYP3A4. *J Natl Cancer Inst* 2002; 94:630-
- Wood AJ. Ethnic differences in drug disposition and response. *Ther Drug Monit* 1998; 20:525-526.
- Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, Vandenbranden M. Studies on the expression and metabolic capabilities of human liver cytochrome P450III A5 (HLP3). *Mol Pharmacol* 1990; 38:207-213.
- Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR. Genetic variability in CYP3A5 and its possible consequences. *Pharmacogenomics* 2004; 5:243-272.
- Yates CR, Zhang W, Song P, Li S, Gaber AO, Kotb M, Honaker MR, Alloway RR, Meibohm B. The Effect of CYP3A5 and MDR1 Polymorphic Expression on Cyclosporine Oral Disposition in Renal Transplant Patients. *J Clin Pharmacol* 2003; 43:555-564.
- Yatscoff RW, Copeland KR, Faraci CJ, Abbott TDx monoclonal antibody assay evaluated for measuring cyclosporine in whole blood. *Clin Chem* 1990; 36:1969-1973.

- Zhao Y, Song M, Guan D, Bi S, Meng J, Li Q, Wang W. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. *Transplant Proc* 2005; 37:178-181.
- Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P, Boyle G, Law Y, Miller S, Lamba J, Burckart GJ. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. *Am J Transplant* 2003; 3:477-483.
- Zheng H, Zeevi A, Schuetz E, Lamba J, McCurry K, Griffith BP, Webber S, Ristich J, Dauber J, Iacono A, Grgurich W, Zaldonis D, McDade K, Zhang J, Burckart GJ. Tacrolimus Dosing in Adult Lung Transplant Patients Is Related to Cytochrome P4503A5 Gene Polymorphism. *J Clin Pharmacol* 2004; 44:135-140.